Clinical Trial Update: Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MBX-2982 as monotherapy for type 2 diabetes completed, assessing efficacy, safety, tolerability, and pharmacokinetics over 4 weeks in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MBX-2982

Snippet

Sponsor: Gilead Sciences | Conditions: Diabetes | Phase 2 | Status: COMPLETED